Repositioning Candidate Details
| Candidate ID: | R1387 |
| Source ID: | DB11635 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Tocofersolan |
| Synonyms: | Tocofersolan; Tocophersolan; TPG-S; TPGS |
| Molecular Formula: | C33H54O5(C2H4O)n |
| SMILES: | -- |
| DrugBank Description: | D-Alpha-tocopheryl polyethylene glycol 1000 succinate (Tocofersolan, Vedrop), has been developed in Europe as an orally bioavailable source of vitamin E in children suffering from cholestasis . Cholestasis is the reduction or stoppage of bile flow, either to impaired secretion by _hepatocytes_ (liver cells) or obstruction , . Tocofersolan is a polyethylene glycol derivative of α-tocopherol and synthetic water-soluble version of . Tocofersolan is an oral treatment of vitamin E deficiency due to digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis. It was approved by the European Medicines Agency (EMA) in June 2009 under the market name Vedrop. Moreover, the agent is capable of demonstrating antioxidant effects that make it a popular component to include in cosmetics and pharmaceuticals as well. In addition to the above, tocofersolan has been studied as a promising application as an absorption enhancer in drug delivery . |
| CAS Number: | 9002-96-4 |
| Molecular Weight: | |
| DrugBank Indication: | Tocofersolan is indicated in vitamin E deficiency caused by digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis from birth (full term newborns) up to 18 years of age . |
| DrugBank Pharmacology: | Because of its increased solubility , , , this medication readily penetrates cells, unlike other types of vitamin E , which are strictly fat-soluble . Specific to cholestasis, tocofersolan normalizes vitamin E levels relieving the symptoms of deficiency because of its facilitation of vitamin E absorption , . |
| DrugBank MoA: | Vitamin E is a major lipo-soluble antioxidant in humans. It acts as a free radical chain breaking molecule, halting the peroxidation of polyunsaturated fatty acids and it plays an important role in maintaining both the stability and integrity of cell membranes . |
| Targets: | P-glycoprotein 1 antagonist |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 5113 | Nutritional deficiency disease | A nutrition disease that is characterized by deficiency of a nutritional element, such as a vitamin, mineral, carbohydrate, protein, fat, or general energy content. https://medlineplus.gov/malnutrition.html | disease of metabolism/acquired metabolic disease/nutrition disease | Details |